Design Therapeutics, Inc.
(NASDAQ: DSGN)

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.

10.200

+0.380 (+3.87%)
Range 9.690 - 10.300   (6.30%)
Open 9.690
Previous Close 9.820
Bid Price 7.590
Bid Volume 8
Ask Price 7.690
Ask Volume 8
Volume 188,378
Value -
Remark
Delayed prices. Updated at 06 Dec 2025 03:07.
Data powered by
View All Events

Loading Chart...

Please login to view stock data and analysis